The exercise period for series TO 8 B warrants issued in connection with the rights issue of units by iZafe Group AB (publ) in November 2019 continues up to and including December 18, 2020. The last day of trading in series TO 8 B warrants on First North Premier Growth is today December 16, 2020. Each series TO 8 B warrant held entitles the holder to subscribe for one new Class B share in iZafe at a price of SEK 3,30 per Class B share. If all the series TO 8 B warrants are exercised, a total of 2,862,129 new Class B shares will be issued, and iZafe will receive proceeds of around SEK 9,4 million before transaction costs.

If your warrants are held by a nominee (in a custodian account like Nordnet or Avanza, an investment savings account (ISK) or endowment policy (KF), you must contact your nominee to subscribe.

If you wish to exercise warrants that are registered in your own name (held in a securities (VP) account), you need to download and complete a Notice of Exercise form (Sw. Anmälningssedel) that can be found at www.hagberganeborn.se or be downloaded directly here.

Note that series TO 8 B warrants will expire and become worthless if the holder does not actively subscribe for shares by December 18, 2020, or alternatively sell their warrants by December 16, 2020.

Advisor
Stockholm Corporate Finance AB is acting as financial advisor, KANTER Advokatbyrå KB as legal advisor and Hagberg & Aneborn Fondkommission AB as issuing agent in connection with the exercise of the warrants.

About Stockholm Corporate Finance
Stockholm Corporate Finance is a Swedish, independent and privately-owned financial advisor which offers financial advisory by taking transaction initiatives, acting in an advisory capacity and assisting with transaction process implementation, working closely with owners, board members and management in listed and privately held companies.

Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which is comprised of 46 M&A advisors and investment banks in 38 countries. Stockholm Corporate Finance is under the supervision of Finansinspektionen (Sweden’s financial supervisory authority) and is a member of industry organization SwedSec Licensiering AB. For more Information, see www.stockholmcorp.se /eng/.

Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B), a leading company focused on the digitalisation of medication handling, is announcing that it is entering into a collaborative partnership with Doro in Sweden as a direct result of the successful take-off with Doro in Norway.

“Thanks to the positive outcome of our partnership with Doro in Norway, we have now also partnered with Doro in Sweden to address the Swedish market. Doro Norway have been delighted with our stable technology and favourable pricing as a valuable complement to their social welfare technology platform,” remarks Anders Segerström, CEO, iZafe Group.

As previously communicated, iZafe Group has initiated a pilot project with Doro in Norway and begun deploying 50 Dosell medication dispensing robots in the homes of care recipients in one of the 30 municipalities in which Doro has implemented its social welfare platform. iZafe Group is today announcing that the partnership has been extended to include Doro in Sweden.

Doro enjoys a unique market position as a leading supplier of social alarms, remote monitoring and alarm reception services in the Swedish market. The partnership with Dosell enables Doro to further expand its offering in the same segment.

“Naturally, we at Doro could not be more pleased about the partnership with iZafe. iZafe is a company that is clearly compatible with our values-based approach and our vision of simplifying life and providing peace of mind to our seniors. Dosell is a state-of-the-art product that makes life easier for seniors and care workers alike. We are looking forward to working with iZafe and have high hopes that they will be able to help us make our current and future offering to our customers even better,” says Martin Puumalainen, Country Director Sweden Business Area Doro Care.

About Doro AB
Doro is a tech company that focuses on seniors. We develop products and services for seniors to make ageing an independent, empowering and rich part of life. Our wide portfolio of products and services for security and care solutions help link generations digitally and create a secure and independent life at home and away from home. Doro is the market leader in social alarms in Sweden, Norway and the UK and the global market leader in smartphones for seniors. Doro is a Swedish company with headquarters in Malmö and sales operations in 27 countries. Shares in Doro are listed on Nasdaq Stockholm. The company had about 1,000 employees in 2019 and net sales of SEK 2,063 million (EUR 195.4 million). Read more about Doro at www.doro.se/corporate.

Stockholm, Sweden and Seattle, USA – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading Life Science company focused on the digitalization of medication management announced it has signed a partnership agreement with Hippo Technologies, Inc., a US based virtual care company, to co-develop a medication dispensing service based on iZafe Groups leading medical management robot Dosell.

iZafe Group and Hippo Technologies will develop a service based on the Dosell robot for customers worldwide using the Hippo Virtual Care platform and products. Dosell is meant for use by patients at home and it will automate dispensing of prescribed medication in dose-packed sachets. The intention is to extend the partnership to include an OEM-version of Dosell.

“Hippo enables virtual care worldwide and is pleased to add this vital function to improve quality of life and health for patients, and to lower the total cost of healthcare,” said Patrick Quinlan, M.D, CEO and co-founder of Hippo Technologies. ”It’s part of Hippo’s goal to make Polymorphic Medicine a reality – our approach to health and care is an optimal blend of self-care, physical care, and virtual care, matching patient needs and preferences with available resources to maximize outcomes.”

The goal with Dosell is to create a full-coverage solution for clinicians and patients while reducing the cost and need for daily home health visits in connection with taking medication. The partnership is an important step for iZafe Group's future investment in digitization of drug dispensing in Europe and the US while broadening Hippo's range of virtual care products and services.

"I am thrilled to get an opportunity to collaborate with one of the leading and most innovative virtual care company to use advances in robotics to solve a significant challenge in healthcare and patient health." comments Anders Segerström, CEO of iZafe Group. “Our work with Hippo Technologies will help close the gap between physical care and virtual care, ultimately improving the delivery of health care.”

About Hippo Technologies, Inc.
Hippo Technologies, Inc., is a global team of healthcare professionals, technologists, experience designers and innovators. Its mission is to serve patients and those who care for them by leading the transformation to virtual care for providers and educators, expanding access to clinical expertise and technologies to improve the quality of healthcare. For more information please visit Hippo Technologies, Inc., or connect with Hippo Technologies on Twitter and LinkedIn.

Media Contact:
Hippo Technologies, Inc.
Jeff Fishburn

Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B), a leading Life Science company focused on the digitalisation of medication handling, is announcing that it will begin delivering a consumer version of Dosell in spring 2021. With the launch, iZafe Group is creating an entirely new consumer market made up of about 200,000 people who already take their medicines using dose-packed sachets and those who keep track of their medications manually using dosette boxes, for example.

  • The consumer version of Dosell is a subscription service that will be the only medication dispensing robot in Sweden that offers the more than 200,000 people in Sweden who receive their medications in dose-packed sachets the opportunity to subscribe to a medication dispensing robot with no need for the health or home care system to provide the equipment.
  • iZafe Group is strengthening its position as the leading developer of digital medication dispensing in the home by offering the first consumer version of the most convenient, safe and economical medication dispensing robot on the market to hundreds of thousands of patients, families and home health care personnel.

“For some time, we have been observing the ground-breaking work of our Italian partners to establish Sempli Farma, a service offered via pharmacies that connects treating physicians with patients and their families through a closed medication dispensing system. Dosell is a key strategic component of Sempli Farma and the time has now come for us to take the initiative and establish a similar system. The Dosell Konsument (Dosell Consumer) service will initially be launched in the Swedish market,” says Anders Segerström, CEO of iZafe Group. “We have invested during the year in product development and upgrading of Dosell and the software to adapt Dosell and the Dosell app to the consumer market, which will also be of tremendous benefit to other customers and users.”

Read more about the forthcoming launch of Dosell Consumer and pre-register for the service here.

Dosell Consumer is one component of the long-term strategy to position iZafe Group as a key player in the digitalisation of home health care. DosPac* from Apoteket AB and MinDos** from Kronans Apotek, for example, have already made it possible for anyone to get their medicines in dose-packed sachets, regardless of whether or not a doctor has prescribed the service. These services, for which the patient pays a small monthly fee, allow the patient and their relatives to decide the safest way to handle their medications.

Dosell Consumer is aimed primarily at the more than 200,000 people who already receive their medications in dose-packed sachets, as well as all of those who choose in the future to pay for medication delivered in sachets via DosPac and MinDos to enhance safety and peace of mind. Dosell Consumer will also appeal to relatives who want to make sure their loved ones take the right medicines at the right time to improve wellbeing and minimise the risk of medication errors. If the person does not take their medication as planned, the Dosell app notifies a relative or care professional, who can act quickly to make sure the medication is taken as prescribed.

Dosell Consumer will provide secure and valuable assistance to people who want to make medication handling safer while giving them more freedom and independence. This will be particularly valuable for older people and those who take multiple medications, for example. Safe and secure medication dispensing increases independence and helps make it possible for people to remain in their own homes longer.

“Dosell substantially improves patient safety because it prevents the user from taking the wrong medicine or missing a dose. We believe this will be hugely appreciated by people who want to offer the service to their parents and other relatives. Users will no longer have to arrange their days around home care visits and can live their lives more freely,” concludes Anders Segerström, CEO of iZafe Group.

In pace with the digitalisation of health care, iZafe Group is setting a new standard for digital dose-packed dispensing in the home that is making digital medication dispensing available to everyone who wants to create a safe and secure setting for medication dispensing.

With products like Dosell Consumer and future patents, iZafe Group is poised to revolutionise at-home care, especially for users who want to live independently at home for longer, but with the peace of mind that comes with knowing relatives and care professionals can step in if something goes wrong.

About Dosell Consumer

  • Dosell Consumer and the Dosell app are a niched version of iZafe’s professional solution, adapted so that that users and relatives can administer and ensure the right medication themselves, without being dependent on care professionals.
  • Alarms can be sent to up to three recipients. The associated app has been adapted and gives the user control over settings including the following:
  • The exact time that medicine can be taken and whether it can be dispensed before the scheduled time. Dispensing earlier than prescribed should always be approved by the treating physician before the intake time is changed.
  • Administration of the individuals who will be recipients of alarm events.
  • When and how alarms are sent via SMS to recipients with a warning that scheduled medicine has not been taken out of Dosell.
  • Dosell Consumer has a dedicated app with a simpler, adapted design for consumer use. The app is compatible with all smart phones and can be downloaded from Google Play and the Apple App Store.
  • Dosell Consumer will be available from sources including pharmacies, local medical centres and partners, as well as via www.dosell.com.
  • Dosell Consumer is a subscription service.
  • Others, such as relatives, can sign up and pay for the Dosell Consumer subscription on behalf of the user.
  • As previously communicated, iZafe Group has a patent pending, which provides important protection for the company’s further development of Dosell as a digital platform. Dosell Consumer is yet another strategic step towards achieving the vision of “The digital ward in the home”.
  • Dosell Consumer will be available for delivery in the second quarter of 2021, but interested consumers can already sign up to ensure access when Dosell Consumer is launched.

Read more about the forthcoming launch of Dosell Consumer and pre-register for the service here.

Do you work in health care or home care?
If you who work in health care or other professional home service provision and would like to know more about how you can work with and offer Dosell in your organisation, please contact:

Tobias Johansson
Sales Manager
iZafe Group AB (publ)
+46 72-567 73 61

About dose-packed sachets from Apoteket AB and Kronans Apotek

*DosPac
Do you or a relative take one or more medications, perhaps at different times of the day? With Apoteket DosPac, you will receive them pre-sorted, in the correct doses and pre-packed in daily dose-packed sachets, so you no longer have to take the time to do that. Each sachet contains the medications you are supposed to take at the same time. Your personal details, the contents of the sachet and when the medication is to be taken are printed on every sachet. That gives you control over making sure you take the right dose at the right time.
Source: https://www.apoteket.se/dospac/

**MinDos
MinDos is a subscription service for dose-packaging of your medications. Instead of receiving your medications in bottles or blister packs, you receive them pre-packed in a roll of individual dose-packed sachets. Each sachet contains all the medications you are supposed to take at the same time. Your personal details, the contents of the sachet and the time each medication should be taken are printed on the sachet.
Source: https://www.kronansapotek.se/tjanster/mindos/

Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B), a leading life science company in the digitalisation of medication management, has announced that its CEO, deputy CEO and board members intend to utilise their options from series TO 8 B to subscribe for shares. During November 2019, iZafe carried out a rights issue of units including TO 8 B shares and options. The subscription period for TO 8 B is in progress and ends on 18 December 2020. The subscription price has been set at SEK 3.30 per B share. The intention to subscribe equates to an issue of 113,471 shares in total.

“During this year, iZafe Group has assumed a position as a leading player in the market for digital medication management. As a pure life science company with our medication dispensing robot Dosell we have made huge progress, and we are continuing to develop the business at a rapid pace. The capital contribution from the subscription to shares in TO 8 B will create further conditions for the commercialisation and widespread introduction of Dosell in the Nordic countries and in Italy,” commented Anders Segerström, CEO of iZafe Group.

The declarations of intent have not been secured via advance transaction, bank guarantee or similar.

Advisors
Stockholm Corporate Finance AB is the financial advisor, KANTER Advokatbyrå KB is the legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing body connected to the option redemption.

About Stockholm Corporate Finance
Stockholm Corporate Finance is an independent, privately owned financial consultancy offering qualified consultancy services relating to capital procurement, changes of ownership, acquisitions, mergers and disposals (M&A) to listed and private companies and their owners. Stockholm Corporate Finance is an exclusive Swedish partner in the global network M&A Worldwide, which is made up of 46 M&A consultants and investment bankers in 38 countries. Stockholm Corporate Finance is a securities company regulated by the Swedish Financial Supervisory Authority and is a member of the sector organisation SwedSec Licensiering AB.

For more information see: www.stockholmcorp.se.

Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading Life Science company focused on the digitalisation of medication handling, is launching an updated version of the Dosell medication dispensing robot. Interest in Dosell continues to grow, and iZafe Group is working with its partners non-stop to upgrade Dosell with new features and achieve even stronger performance. iZafe Group has established an internal Customer Success team that is responsible for all communication with partners and customers. The goal is to identify preferences concerning the development of Dosell and the associated system at an early stage.

“We are receiving valuable ongoing feedback from pilot projects and our partners in the Nordic countries and Italy, which means we can prioritise the right issues to further improve Dosell. In the light of the feedback we have documented, the past six months have been a period of intense development and investments in products, technology and software. IZafe group is reinforcing its leading position in a powerfully growing market through ongoing investments in products and the market, combined with close cooperation with partners,” says Anders Segerström, CEO of iZafe Group.

The sale of the company’s security business, iZafe Security, created the necessary scope for continuous investments in product development and commercialisation of Dosell. The company has released numerous new features in pace with several public procurement processes and the launch of additional pilot projects. In parallel, the partner network has been expanded and international establishment is growing.

A selection of recently developed new or updated features:

  • A new safety feature that provides the option to dispense dose-packed sachets using the “wait until button is pressed” has been launched.
    • When it is time to dispense medication, the user must press the button to get the medicine. If they do not press the button within a predetermined time, the medication is locked inside Dosell.
  • A demo mode has been developed and introduced to make it easier to present Dosell’s features and alarm handling at training sessions, for example.
  • The option to dispense dose-packed sachets at non-scheduled times makes the system more flexible for users, so that Dosell adjusts to their daily routines and not the reverse.
  • A feature for accessing information about when the next dose will be dispensed.
  • Improved handling of minutes in OCR.
  • The red LED light that shines in the dose compartment when the user has not removed the sachet in time goes out automatically when the sachet is removed. In the past, the user had to press a button to turn off the light. 
  • Validation of Finnish dose-packed sachets.
  • The company has invested in and developed software and systems, including other functionalities to improve how Dosell communicates with the server, making easier to support and facilitate the work of partners.
  • A feature to determine whether the placement of the dispensing robot should be changed to improve coverage.
  • Medication dispensing robots with built-in rechargeable batteries and 48-hour battery backup will be launched early next year to further enhance safety.
  • A simplified start-up process for new users to connect to Dosell will be launched in Q1 2021.

In November 2019 iZafe Group AB (publ) (“iZafe” or “the Company”) carried out a rights issue of units, consisting of shares and series TO 8 B warrants. The subscription period for the series TO 8 B warrants begins on Friday, December 4, 2020 and continues up to and including December 18, 2020.

One (1) series TO 8 B warrant entitles the holder to subscribe for one (1) new Class B share in iZafe. Under the terms of the warrants the exercise price is SEK 3,30. If all the warrants are exercised, iZafe will receive proceeds of around SEK 9,4 million before issue costs.

Summary instructions and important dates

• Warrant holders wishing to exercise these warrants to subscribe for Class B shares must notify this themselves in good time before Friday, December 18, 2020. After this date the warrants will expire and become worthless.

• Holders who do not wish to exercise their warrants are recommended to sell them. The warrants will be traded up to and including Wednesday, December 16, 2020.

Detailed instructions for holders of warrants are given below.

Exercise of warrants held by a nominee
Those whose series TO 8 B warrants are held by a nominee [held in a custodian account, investment savings account (ISK) or endowment policy (KF)] must notify that they wish to exercise warrants by contacting their nominee and following the nominee’s instructions for subscription and payment. This should be done in good time before Wednesday, December 16, 2020, since different nominees have differing processing times.

Exercise of warrants registered in own name
Holders of series TO 8 B warrants that are registered in their own name [holdings in a securities (VP) account] must notify that they wish to exercise warrants by completing and submitting a Notice of Exercise for iZafe’s series TO 8 B warrants so that it is received by the issuing agent Hagberg & Aneborn Fondkommission by 15:00 CET on Friday, December 18, 2020 at latest.

The Notice of Exercise can be downloaded from:

iZafe’s website, www.izafe.se/teckningsoptioner; and

Hagberg & Aneborn Fondkommission’s website, www.hagberganeborn.se

Note that payment for the new shares must also be received by Hagberg & Aneborn Fondkommission by December 18, 2020 at the latest in accordance with the instructions in the Notice of Exercise.

Trading in iZafe series TO 8 B warrants
Holders who do not wish to exercise their warrants are recommended to sell them on First North Premium Growth so that another party can exercise the warrants. The iZafe series TO 8 B warrant is being traded on First North Premium Growth up to and including Wednesday, December 16, 2020. Warrants that are not exercised before December 18, 2020 or sold before December 16, 2020 will expire and become worthless.

Result and delivery of new shares
The result of the exercise of series TO 8 B warrants will be published in a press release on or around Friday, December 18, 2020.

The new shares will be delivered to the subscribers’ accounts as interim shares (IS). They will then be admitted to trading on First North Premium Growth as soon as the issue has been registered with Bolagsverket (the Swedish companies registration office) and Euroclear.

Full terms and conditions for iZafe series TO 8 B
Full terms and conditions for iZafe series TO 8 B are available in the information memorandum prepared by iZafe’s Board of Directors in conjunction with the rights issue in 2019.

The memorandum can be downloaded from iZafe’s website www.izafe.se/teckningsoptioner or be downloaded directly here.

ISIN code
The ISIN code for iZafe series TO 8 B is SE0013409406.

Number of series TO 8 B warrants and potential proceeds
The number of warrants amounts to 2,862,129. If all the warrants are fully exercised, iZafe will receive proceeds of around SEK 9,4 million, before issue costs.

Advisor
Stockholm Corporate Finance AB is acting as financial advisor, KANTER advokatbyrå KB as legal advisor and Hagberg & Aneborn Fondkommission AB as issuing agency in connection with the exercise of the warrants.

About Stockholm Corporate Finance
Stockholm Corporate Finance is an independent privately-owned financial advisor offering expert advisory services relating to capital raising, changes in ownership, and mergers, acquisitions and divestments (M&A) for listed and privately held companies and their owners. Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which is comprised of 46 M&A advisors and investment banks in 38 countries. Stockholm Corporate Finance is under the supervision of Finansinspektionen (Sweden’s financial supervisory authority) and is a member of industry organization SwedSec Licensiering AB. For more information see www.stockholmcorp.se/eng/.

The subscription price for warrant TO 8 B iZafe Group AB (“iZafe” or “the Company”) has been set at SEK 3.30 in accordance with the applicable option terms. One (1) warrant TO 8 B entitles the holder to subscribe for one (1) B share in iZafe. Subscription of Class B shares with the support of warrants can take place from and including 4 December 2020 to and including 18 December 2020. If all warrants of series TO 8 B are exercised, the Company will receive SEK 9,445,000 before issue costs.

Conditions in summary


  • Subscription period: 4 – 18 December 2020 (subscription takes place through simultaneous cash payment).
  • Number of warrants: 2,862,129 warrants of series TO 8 B.
  • Subscription price: The holder of warrants has the right to subscribe for one new B share in iZafe for each warrant at the subscription price of SEK 3.30 per share.
  • Issue volume: When full exercise of all warrants, SEK 9,445,026 is added to iZafe.
  • Last day for trading in warrants: 16 December 2020.

Stockholm, Sverige – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading Life Science company focused on the digitalisation of medication management, is announcing that it has signed a partnership agreement with Vivago, a Finnish provider of safety and well-being solutions for preventive care. In conjunction, iZafe and Vivago are launching an initial joint pilot project covering 20 Dosell medication dispensing robots.

The results of the pilot project will be used as decision input for a future commercial arrangement based on an integrated solution involving automated dispensing of medication in dose-packed sachets from dispensing robots. The goal is to create a full-coverage solution for users while reducing the need for home health visits in connection with taking medication.

“We are proud of the partnership and are looking forward to working with Vivago to further develop the industry in Finland. In the first stage, we will perform a joint market analysis to build knowledge about the Finnish market. We are especially pleased that our partnership has already resulted in a strategically important pilot project.” comments Anders Segerström CEO, iZafe Group.

Major training initiatives were carried out in the autumn to prepare for the pilot project, which is expected to begin immediately after the end of the year. Twenty people will be using Dosell to manage their medication during the pilot project.

“We are delighted by the partnership between Vivago and iZafe. The partnership will be a key step in Vivago’s future ventures in the digitalisation of medication dispensing in Finland while reinforcing our service offering. The partnership with iZafe and their Dosell digital medication dispenser makes a more comprehensive service offering to our customers in Finland possible. Vivago’s health and well-being solutions combined with Dosell will enhance safety and provide better care to our elderly people.” Says Niina Vilkas, CEO Vivago Ltd.


About Vivago
Vivago develops smart safety and wellbeing solutions for preventive care by monitoring users’ health status in real-time and wellbeing 24/7. The Vivago solution includes all features required for nurse call systems and covers the entire chain of care from home care and assisted living to rehabilitation centres and hospitals. More than 100,000 people use Vivago solutions every single day. Full digitalisation of health status monitoring is opening a revolutionary path to changing care delivery from reactive to preventive while tailoring entirely patient-centred and results-driven care.

Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – a leading Life Science company specializing in healthcare services digitalization announces the opportunity for shareholders, media, and other stakeholders to ask company-related questions in connection with its Third Quarter 2020 report. The report will be available to the public on on November 9, 2020 at 08.30 (8:30 a.m.) CET. Questions will be answered by Chief Executive Officer Anders Segerström in a video presentation that will be published on November 18, 2020 on iZafe's website under the heading Investor Relations.

Please send your questions to  before 17:00 (5 p.m.) CET on November 10, 2020. You can also use an online form to send your questions. This form is available on iZafe's website, Investor Relations page.

Webbdesign av Comlog Webbyrå Stockholm